• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Evotec and Oxford create novel LAB282 partnership

Evotec and Oxford create novel LAB282 partnership

November 10, 2016
CenterWatch Staff

Evotec has announced a novel strategic partnership with the University of Oxford, the university's research commercialization company Oxford University Innovation (OUI) and Oxford Sciences Innovation, an IP investment company dedicated to a single university (OSI) aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics. Projects will be sourced exclusively from Oxford University researchers via OUI across any therapeutic area and for any therapeutic modality and will be aided by a drug discovery expert in residence seconded by Evotec to the LAB282 initiative and embedded in the university.

"LAB282" will be supported by a fund of ₤ 13 million led by OSI for an initial period of three years. The goal is to accelerate the achievement of preclinical proof-of-concept for new drugs and to generate new spin-out companies. The development of new treatments and cures for serious and debilitating diseases will help patients live longer and better lives as well as reduce the burden on global healthcare systems.

Evotec will exclusively contribute its drug discovery expertise and platforms to select projects and develop them further. Evotec will be entitled to equity in new LAB282 spin-out companies together with Oxford University and its academic researchers and together with OSI will have the right to co-invest in seed financing rounds.

Dr. Cord Dohrmann, chief scientific officer of Evotec, said, "LAB282 is a highly innovative partnership that elegantly combines core strengths of academia, biotech, venture capital and strong links to Pharma under one ‘roof.’ Casting a wide net in terms of indications and technologies, it is designed to accelerate in particular first-in-class and potentially disruptive early-stage projects to value inflection points that will facilitate the formation of companies. We are very proud to be part of this exciting endeavor with such highly distinguished partners and are convinced that this model will become a blueprint of effectively and efficiently translating academic science into highly differentiated product opportunities."

Dr Adam Stoten, head of Technology Transfer, Life Sciences at OUI, said, "This pioneering approach addresses a major unmet need by engaging LAB282's partners, together offering world-class medical research, commercial drug discovery expertise and facilities, and significant investment resources. Today's announcement provides another great example of how U.K. universities are at the forefront of collaborative public-private drug discovery partnerships with the goal of patient benefit."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing